There is a certain tunnelvision to the Cortex shareholder view--like it's only happening to them, and that there is some unique reason for it that must be ferreted out. I keep pointing out that there is evidence to the contrary. You respond with a comment about boosterism.
I am surprised that Cortex went down this much--and that Targacept went down this much--and that Neurogen went down this much. Now that I think of it, Cypress Biosciences went down a lot after its milnacipran Phase III boost. Color me surprised, but to label it as a Cortex-centric phenomenon is (and I am not singling you out individually) to miss the larger point. And it's being missed repeatedly, so I am starting to get the impression that there is a degree of masochism going on here. I'm unhappy about the price drop, it makes me anxious, but I don't get much of a thrill trying to figure out a scenario that belongs to Cortex and Cortex alone, when in fact it has plenty of company. Life is hard enough without adding more pain without necessity or reason.
NeuroInvestment
Market Data 
Markets 
AI
